About Enyo Pharma
Enyo Pharma is a Healthcare company based in Lyon (France) founded in 2014. Therapeutics are developed for diseases with impaired kidney function. Enyo Pharma has raised $120.34 million across 8 funding rounds from investors including Orbimed, Bpifrance and Andera Partners. Enyo Pharma offers products and services including Vonafexor. Its focus areas include Life Sciences, Gastroenterology, Drugs and Liver Diseases. Its legal entity is ENYO Pharma SA.
Company details
Enyo Pharma was founded in 2014 and is based in Lyon, France. Therapeutics targeting diseases associated with impaired kidney function are developed by the company within the pharmaceutical sector. Operations focus on small molecules such as VONAFEXOR, which exhibits fibrolytic and anti-inflammatory effects in both kidney and liver tissues. The companys activities center on advancing treatments for organ-specific conditions.
- Headquarters Lyon, France
- SectorsHealthcare
- Email••••••••
- Website enyopharma.com
- Social LinkedIn X YouTube
- Legal Name Enyo Pharma Sa
- Total Equity Funding$120.34M (USD)
in 8 rounds
- Latest Funding Round$6.87M (USD), Series C
Jun 2025
- InvestorsOrbimed
& 9 more
Products & Services of Enyo Pharma
Enyo Pharma offers a comprehensive portfolio of products and services, including Vonafexor.
Small molecule treating kidney diseases like Alport Syndrome
Apps and channels of Enyo Pharma
its YouTube channel ENYO Pharma has 32 subscribers and 10 videos.
Videos from Enyo Pharma
The most watched videos on Enyo Pharma's YouTube channel, ENYO Pharma (32 subscribers). Click a video to play it here.
More on ENYO Pharma.
Funding Insights of Enyo Pharma
Enyo Pharma has successfully raised a total of $120.34M across 8 strategic funding rounds. The most recent funding activity was a Series C round of $6.87 million completed in June 2025. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $120.34M
- Total Rounds 8
- Last Round Series C — $6.87M
- Investors Count 10
All 8 funding rounds of Enyo Pharma with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jun 2025 | $6.87M | Series C | – | – | |
| Jan 2024 | $42.85M | Series C | – | Orbimed, Morningside | |
| Oct 2018 | $2.84M | Grant | – | – | |
| Jun 2018 | $46.63M | Series B | – | Orbimed | |
| Dec 2016 | $2.66M | Grant | – | – | |
| Nov 2016 | $2.76M | Grant | – | – | |
| Feb 2016 | $23.99M | Series A | – | Sofinnova Partners | |
| Jun 2015 | Seed | – | – |
10 investors in total: 10 institutional.
Investors in Enyo Pharma
Enyo Pharma has secured backing from 10 investors, including venture fund and institutional investors. Prominent investors backing the company include Orbimed, Bpifrance and Andera Partners.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Investments are made by OrbiMed in global healthcare innovations across biopharmaceuticals and related fields. | 1989 | orbimed.com | New York, United States | |
Multiple sectors are invested in by Morningside, a VC fund. | morningside.com | Newton, United States | ||
Capital is provided to firms for growth, buyouts, and acquisitions. | 2001 | anderapartners.com | Paris, France | |
Government agency and accelerator focusing on innovative startups and SMEs | eicfund.eu | Brussels, Belgium | ||
Sofinnova Partners is focused on life sciences and healthcare investments. | sofinnovapartners.com | Paris, France | ||
Investments are directed toward early-stage healthcare companies in France. | 2000 | inserm-transfert.fr | Paris, France | |
A European life sciences venture capital investor is operated. | vesaliusbiocapital-4.com | Contern, Luxembourg | ||
Corporate consultancy, advisory, and funding services are provided to businesses. | 2012 | bpifrance.com | Maisons Alfort, France | |
Develops innovative technologies for a suite of nutritional raw materials. | 2003 | innobio.cn | Dalian, China | |
Government entites focused on freedom, democracy, equality and the rule of law, promoting peace and stability | 1958 | europa.eu | Brussels, Belgium |
Investor details for Enyo Pharma
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Enyo Pharma
18 people are tracked at Enyo Pharma (6 in leadership, 7 in board & advisors, 5 in team).
| Name | Role | Group |
|---|---|---|
Claudi MIQUEL | VP Legal | Leadership |
Jacky Vonderscher | Co-Founder & CEO | Leadership |
enoît de Chassey | Co-Founder & Head, Drug Discovery Platform | Leadership |
Pietro Scalfaro | SVP, Chief Medical Officer & Head, Clinical Development | Leadership |
Virginie Vidal | Head Of Clinical Operations | Leadership |
Pete Leone | Head, Business Development & Licensing | Leadership |
Timothy M. Wright | Board Member | Board & advisors |
Patrice André | Co-Founder & Medical Advisor | Board & advisors |
Vincent Lotteau | Co-Founder & Scientific Advisor | Board & advisors |
Jason Dinges | Board Member | Board & advisors |
Laurent Arthaud | Board Member | Board & advisors |
Maina Bhaman | Board Member | Board & advisors |
Iain D. Dukes | Board Member | Board & advisors |
Nathalie DREVET | Quality Assurance Manager | Team |
Delphine Buforn | Human Resources and G&A Manager | Team |
Marion Odoul | Clinical Project Manager | Team |
Elodie COCCO | Accountant | Team |
Isabelle Martin | Clinical Project Manager | Team |
Complete people profiles for Enyo Pharma
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Enyo Pharma
3 dated milestones of Enyo Pharma across 11 years, from founding to its latest funding, stage changes and deals.
- Founded Enyo Pharma is founded.
- Funding First funding round.
- Funding Latest funding round, Series C, of $6.9M.
Web traffic of Enyo Pharma
The website of Enyo Pharma (enyopharma.com) receives about 2K visits a month.
- Monthly visits2K
▲ 84.2% vs previous month
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Enyo Pharma
Complete news archive for Enyo Pharma
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Enyo Pharma
Enyo Pharma was founded in 2014 and raised its 1st funding round 1 year after it was founded.
Enyo Pharma is headquartered in Lyon, France. It is registered at Lyon, Auvergne-rhone-alpes, France.
Enyo Pharma is a funded company, having raised a total of $120.34M across 8 funding rounds to date.
Enyo Pharma was founded in 2014 and is based in Lyon, France. Therapeutics targeting diseases associated with impaired kidney function are developed by the company within the pharmaceutical sector. Operations focus on small molecules such as VONAFEXOR, which exhibits fibrolytic and anti-inflammatory effects in both kidney and liver tissues. The companys activities center on advancing treatments for organ-specific conditions.
Enyo Pharma offers Vonafexor.
Enyo Pharma has 10 investors. Key investors include Orbimed, Bpifrance, Andera Partners, European Union, and Inserm Transfert.
Enyo Pharma operates through Enyo Pharma Sa.